Alexion Pharmaceuticals, Inc.

About Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company dedicated to developing and delivering life-changing therapies for patients with rare diseases. Founded in 1992, the company has established itself as a leader in the field of complement biology, focusing on innovative treatments that address unmet medical needs.

With a commitment to scientific excellence, Alexion invests heavily in research and development to discover new therapies that can transform the lives of patients suffering from severe and complex conditions. The company’s flagship product, Soliris, is a groundbreaking treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS).

In addition to its focus on rare diseases, Alexion is expanding its portfolio to include therapies for other serious conditions, including neurology and hematology. The company operates globally, with a strong presence in North America, Europe, and Asia, ensuring that its innovative therapies reach patients around the world.

Alexion is also committed to corporate social responsibility, actively engaging in initiatives that support patient communities and promote access to healthcare. The company believes in the importance of collaboration with healthcare professionals, patients, and advocacy groups to drive progress in the treatment of rare diseases.

As part of its vision, Alexion aims to redefine the standard of care for patients with rare diseases, striving to provide hope and improved quality of life through its innovative therapies. The company’s dedication to patients is reflected in its mission to deliver life-changing medicines and to be a trusted partner in the healthcare community.

• Founded: 1992
• Headquarters: United Kingdom
• Core Focus: Rare diseases and complement biology
• Flagship Product: Soliris